Osiris Therapeutics, Inc. was founded in 1992 and is a leading player in the biotechnology, medical devices, and marketing industries. The company, based in Columbia, Maryland, has gained recognition for its breakthroughs in regenerative medicine products. A significant milestone in its journey was achieving the distinction of developing the world’s first approved stem cell drug. With a focus on innovation in regenerative medicine, including bioengineering, stem cell research, and viable tissue-based products, Osiris has made remarkable strides in orthopaedics, sports medicine, and wound care with products such as BIO4™, Cartiform®, and Grafix®.
Osiris Therapeutics' remarkable progress has continued to attract investment, with its most recent Venture Round investment at 06 July 2018 drawing interest from SOSV and Arvind Gupta. The company's dedication to advancing the science of cellular regenerative medicine, coupled with its commercial success and ongoing research and development in biotechnology, positions it as an intriguing prospect for venture capital investors.
For further information on Osiris Therapeutics, Inc., please visit the company's website, www.Osiris.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 2 |
|
06 Jul 2018 |
| Post-IPO Equity | $15.00M | 1 | Mesoblast | 09 Apr 2014 |
| Post-IPO Debt | $30.00M | 1 | Friedli Corporate Finance | 09 Oct 2007 |
| Private Equity Round | $50.00M | - | 09 Jun 2005 |
No recent news or press coverage available for Osiris Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
